We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Delivers Second Pre-Clinical Candidate in Alliance with GlaxoSmithKline
News

Galapagos Delivers Second Pre-Clinical Candidate in Alliance with GlaxoSmithKline

Galapagos Delivers Second Pre-Clinical Candidate in Alliance with GlaxoSmithKline
News

Galapagos Delivers Second Pre-Clinical Candidate in Alliance with GlaxoSmithKline

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Delivers Second Pre-Clinical Candidate in Alliance with GlaxoSmithKline"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that it has successfully identified a second pre-clinical candidate compound in its osteoarthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached a milestone on another compound in the alliance. Together these milestones trigger payments totaling €5.2 million to Galapagos.

This pre-clinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. The candidate was developed by Galapagos against a novel target discovered with Galapagos' proprietary platform. The molecule is now ready for scale up chemistry and comprehensive safety evaluation, with the goal of entering Phase I clinical research in 2010.

"Six months after announcing our first pre-clinical candidate in this alliance, we are pleased to announce the delivery of a second candidate drug," said Onno van de Stolpe, Chief Executive Officer of Galapagos.

"This achievement illustrates that Galapagos is successfully progressing multiple programs across each alliance, thereby increasing the likelihood of producing novel, disease-modifying therapeutics."
Advertisement